We are live on ! Find out more
CLDI icon

Calidi Biotherapeutics
CLDI

31 hedge funds and large institutions have $523K invested in Calidi Biotherapeutics in 2024 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

11% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 9

3% more funds holding

Funds holding: 30 → 31 (+1)

0.03% less ownership

Funds ownership: 0.06% → 0.03% (-0.03%)

43% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 7

66% less capital invested

Capital invested by funds: $1.53M → $523K (-$1.01M)

Holders
31
Holders Change
+1
Holders Change %
+3.33%
% of All Funds
0.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
4
Reduced
7
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CI
CPR Investments
Michigan
+$130K
2
RCI
RS Crum Inc
California
+$67.3K
3
DIM
Delta Investment Management
California
+$53.2K
4
Citadel Advisors
Citadel Advisors
Florida
+$33.5K
5
HF
HRT Financial
New York
+$23.3K

Top Sellers

Rank Fund Capital Flow
1
MC
Meteora Capital
Florida
-$141K
2
CCC
Cable Car Capital
California
-$123K
3
SAMC
Spectrum Asset Management (California)
California
-$94.1K
4
AMH
Apollo Management Holdings
New York
-$70.6K
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$60.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
RWI
1
Red Wave Investments
Pennsylvania
$125K -$5.33K -167 -3%
CI
2
CPR Investments
Michigan
$112K +$130K +4,084 +701%
RCI
3
RS Crum Inc
California
$52.7K +$67.3K +2,106 +2,340%
DIM
4
Delta Investment Management
California
$42K +$53.2K +1,667 +1,961%
Citadel Advisors
5
Citadel Advisors
Florida
$25.2K +$33.5K +1,049 New
FC
6
Finepoint Capital
Massachusetts
$25K – – –
HF
7
HRT Financial
New York
$20K +$23.3K +728 +622%
DCM
8
Driehaus Capital Management
Illinois
$18.9K – – –
PAMP
9
Polar Asset Management Partners
Ontario, Canada
$12.8K – – –
HCM
10
Highbridge Capital Management
New York
$12.5K +$16.6K +521 New
Marshall Wace
11
Marshall Wace
United Kingdom
$12.4K – – –
GL
12
Governors Lane
New York
$9.47K -$12.6K -394 -50%
XT
13
XTX Topco
Cayman Islands
$8.59K +$11.4K +358 New
6CM
14
683 Capital Management
New York
$7.58K -$2.68K -84 -21%
MF
15
Magnetar Financial
Illinois
$6.31K -$7.86K -246 -47%
VF
16
Virtu Financial
New York
$5K -$4.31K -135 -38%
DIM
17
DLK Investment Management
California
$4.16K +$5.53K +173 New
Morgan Stanley
18
Morgan Stanley
New York
$3.84K – – –
Vanguard Group
19
Vanguard Group
Pennsylvania
$2.99K – – –
State Street
20
State Street
Massachusetts
$2.58K +$3.45K +108 New
CCC
21
Cable Car Capital
California
$2.25K -$123K -3,846 -98%
TSS
22
Two Sigma Securities
New York
$2.23K +$2.97K +93 New
Creative Planning
23
Creative Planning
Kansas
$2K – – –
Cetera Investment Advisers
24
Cetera Investment Advisers
Illinois
$2K +$2.65K +83 New
FCI
25
Financial Counselors Inc
Kansas
$2K +$2.65K +83 New
1
2

CLDI Hedge Fund Activity: Q2 2024 in Review

31 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics (CLDI) for Q2 2024, worth a combined $523K — down 66% from $1.53M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new CLDI positions and 9 closed out — a net gain of 1 holder — while 4 added to existing stakes and 7 trimmed.

The largest buyer was CPR Investments, adding an estimated $130K. The largest seller was Meteora Capital, exiting entirely with an estimated $141K sold.

  • 31 institutional investors held Calidi Biotherapeutics (CLDI) as of Q2 2024, up from 30 in Q1 2024.
  • Funds reported $523K of Calidi Biotherapeutics stock for Q2 2024, down 66% quarter-over-quarter.
  • 10 funds opened new Calidi Biotherapeutics positions in Q2 2024 and 9 closed out, a net change of +1 holder.
  • The largest Calidi Biotherapeutics buyer in Q2 2024 was CPR Investments, an estimated $130K added.
  • The largest Calidi Biotherapeutics seller in Q2 2024 was Meteora Capital, an estimated $141K sold.

Based on aggregated 13F filings for Q2 2024.